Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18889198 | 0.94 | RIPK1 (0.81) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18932473 | 0.88 | RIPK1 (0.77) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889252 | 0.88 | RIPK1 (0.77) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889246 | 0.88 | RIPK1 (1.00) | RIPK1L3MBTL1ALDH1A1POLBSLC9A1 | |
| SCHEMBL18889253 | 0.85 | RIPK1 (0.78) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889288 | 0.85 | RIPK1 (0.81) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889266 | 0.84 | RIPK1 (1.00) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889228 | 0.84 | RIPK1 (0.80) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889214 | 0.84 | RIPK1 (0.80) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18889244 | 0.83 | RIPK1 (1.00) | RIPK1L3MBTL1ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | claimed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | claimed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | claimed |
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3176163-B1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | IAC IN NAT UNIV CHUNGNAM (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| EP-3176163-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) | 2017-06-07 | — | — | EP | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885L3MBTL1 2632/4885ALDH1A1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.